(NASDAQ:TNXP) shares are surging up more than 30% on winning monkey pox patent. More than 43,000 traded at $3.22 this pre-market.

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-801 Smallpox and Monkeypox Vaccine and Recombinant Pox Virus (RPV) Platform Technology

Strengthens Patent Portfolio Protecting Horsepox-Based Live Virus Vaccines

TNX-1840 and TNX-1850 are Potential RPV Vaccines Designed to Protect Against COVID-19

Confirms Leadership Position in Synthetic Biology

Statutory Term of New Patent Expected to Provide Exclusivity Until 2037

CHATHAM, N.J., June 01, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage biopharmaceutical company, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,345,896 to the Company on May 31, 2022. This patent, entitled “Synthetic Chimeric Poxviruses,” includes claims covering synthetic horsepox virus, the basis for the Company’s TNX-8011 vaccine in development to protect against monkeypox and smallpox and for the Company’s Recombinant Pox Virus (RPV) platform to protect against other pathogens, including SARS-CoV-2. This patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term adjustments.


NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.